A Universal Linker for Potent ADCs: From Best-in-Class Efficacies to Keystone-Enabling Designs for Synergistic Dual Payload & Immune-Stimulating ADCs - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

A Universal Linker for Potent ADCs: From Best-in-Class Efficacies to Keystone-Enabling Designs for Synergistic Dual Payload & Immune-Stimulating ADCs

2:30 pm - Tuesday 13th October 2026

Introducing OmniLink universal linker for rapid screening of optimal antibody-payload combinations with homogenous high DAR
Showcasing OmniLink-constructed ADCs with different payloads, with exatecan and DM1 as illustrative examples versus current leading ADCs for the same payload classes
Unveiling applications in novel ADC designs such as dual payload and immune-stimulating ADCs

Speakers:

Young-Sun Lin

Young-Sun Lin

Chief Scientific Officer

Tripartite Therapeutics, Inc.